Daishia Hord Joins AVBCC Panel on GLP-1s, Obesity and Cancer Prevention

We’re proud to share that Daishia Hord, HealthDyne Regional Vice President of Sales, will join healthcare leaders at the Association for Value-Based Cancer Care (AVBCC) for a timely discussion at the intersection of obesity, oncology and patient access.

The session, “Obesity, GLP-1s, and Cancer Prevention: Are We Witnessing the Next Revolution in Oncology?” will take place on October 8, 2026, from 2:00–2:50 PM ET at the New York Athletic Club in New York City.

Daishia will bring the patient access perspective to the panel, exploring what emerging evidence around GLP-1s and cancer prevention could mean for coverage decisions, affordability and the ability of patients to start and stay on therapy.

Why This Conversation Matters Now

GLP-1 therapies have already reshaped obesity management, and researchers are now asking if they can also reshape how we think about cancer prevention. Early evidence points to a lower rate of obesity-associated cancers, and some studies suggest these medications may even slow metastatic progression in patients who develop cancer. At the same time, randomized clinical trials haven’t yet confirmed a broad, causal cancer-prevention benefit, leaving open questions about mechanism, timing, and which patients stand to gain the most.

That gap between promising signal and proven outcome is exactly where policy, payment, and access decisions get complicated, and it’s where Daishia will focus her contribution to the panel.

When Promising Science Meets Real World Access

As the discussion moves from the science to the real-world implications, Daishia will bring an important patient access perspective to the conversation. That includes how payers determine when the evidence is strong enough to support broader coverage, whether a potential long-term cancer-prevention benefit changes the value equation for employers and other purchasers, and how affordability, persistence and stigma influence whether patients actually begin and remain on treatment.

Those consideration are closely connected. Access to GLP-1s has never been a simple “covered or not covered” decision. It encompasses what a patient can afford, how easily they can obtain a prescription, the clinical support available throughout treatment and what happens when coverage or circumstances change.

If the oncology community is going to take a possible cancer-prevention benefit seriously, the access conversation has to keep pace with the science. Otherwise, even a proven benefit won’t reach the patients who need it.

A Timely Seat at the Table

As payers, employers, and health systems continue to weigh the value of GLP-1 coverage, panels like this one are shaping the frameworks that will guide decisions for years to come.

We’re glad Daishia will be part of the conversation, representing the patient-access lens alongside her fellow panelists.